Glycoprotein IIb/IIIa inhibitors for NSTEACS

When immediate access to a cardiac catheterisation laboratory is not available, glycoprotein IIb/IIIa inhibitors (eg eptifibatide, tirofiban) may be used in patients with non–ST elevation acute coronary syndrome (NSTEACS) who are at high or very high risk (see Overview of management of non-ST elevation acute coronary syndrome (NSTEACS)). The decision to use a glycoprotein IIb/IIIa inhibitor is usually made with specialist consultation.

If a glycoprotein IIb/IIIa inhibitor is used, dose according to the local protocol or the product information.

Glycoprotein IIb/IIIa inhibitors are not indicated for low-risk unstable angina.